Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.910 +0.680 (+21.05%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexaria Bioscience Corp < Previous 1 2 ... 13 14 15 16 17 18 19 20 21 ... 23 24 Next > Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry May 11, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands May 06, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands May 06, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands May 05, 2022 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands May 05, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH April 29, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform April 28, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform April 28, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data April 27, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices April 25, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices April 25, 2022 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs April 21, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs April 21, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs April 21, 2022 - 25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date April 19, 2022 Via Investor Brand Network Exposures Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date April 19, 2022 Via CannabisNewsWire Exposures Product Safety Lexaria (NASDAQ: LEXX) Advances Human Nicotine Study, Announces New Program with Altria April 19, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Commences Multi-Week Human Clinical Hypertension Study April 19, 2022 - HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits - This study is designed to enhance Lexaria's probabilities of success with its... From Lexaria Bioscience Corp. Via AccessWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria April 18, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Results from Hypertension Study April 18, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study April 14, 2022 Via CannabisNewsWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study April 14, 2022 Via Investor Brand Network Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results April 14, 2022 Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug... From Lexaria Bioscience Corp. Via AccessWire Lexaria Bioscience (NASDAQ: LEXX) Issues Update on Human Nicotine Study April 13, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1 April 12, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1 April 12, 2022 Via CannabisNewsWire Lexaria Bioscience (NASDAQ: LEXX) Begins Nicotine Formulation Creation, Evaluation Program April 12, 2022 Via Investor Brand Network Lexaria Provides Update on Human Nicotine Study NIC-H22-1 April 12, 2022 - Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 /... From Lexaria Bioscience Corp. Via AccessWire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program April 11, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program April 11, 2022 Via CannabisNewsWire < Previous 1 2 ... 13 14 15 16 17 18 19 20 21 ... 23 24 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.